Status: Recruiting
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.
Participants needed: 232
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SparX Biotech(Jiangsu) Co., Ltd.Updated: Sep 24, 2024Locations: 4
Eligibility criteria
Males and females ≥18 years of age who comprehend, are not incarcerated, are wil... [+14]
History of prior malignancy, except for adequately treated in situ cancer, basal... [+9]